英文版
CONSENSUS
STATEMENTS
EXPERT CONSENSUS DOCUMENT
World Heart Federation expert consensus
statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
Glenn N. Levine, Young-Hoon Jeong, Shinya Goto, Jeffrey L. Anderson, Yong Huo, Jessica L. Mega, Kathryn Taubert and Sidney C. Smith Jr
Abstract | Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large,
phase III, randomized, controlled trials of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different ‘therapeutic window’ of on treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the ‘East Asian paradox’ has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.
Levine, G. N. et al. Nat. Rev. Cardiol. advance online publication 26 August 2014; Introduction
Baylor College of
Medicine and Michael E. DeBakey VA Medical Center, USA (G.N.L.). Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, South Korea (Y. H.J.). Department of Medicine (Cardiology), Tokai University School of Medicine, Japan (S.G.). Intermountain Medical Center, University of Utah School of Medicine, USA (J.L.A.). Department of Cardiology, Peking University First
Hospital, China (Y.H.). Brigham and Women’s Hospital, TIMI Study Group, USA (J.L.M.). World Heart Federation, Switzerland (K.T.). Division of Cardiology, University of North Carolina, 160 Dental Circle, CB 7075,
Chapel Hill, NC 27599, USA (S.C.S.).Correspondence to: S.C.S.
At the 65th World Health Assembly in May 2012, all 194 WHO member states endorsed a target to reduce pre-mature deaths caused by noncommunicable diseases by 25% by 2025.1 Cardiovascular diseases are the leading cause of death and disability among the noncommuni-cable diseases.2 Therefore, effective treatment of patients with atherosclerotic coronary artery disease—both those with acute coronary syndrome (ACS) and those under-going percutaneous coronary intervention (PCI)—is an important strategy to reduce the rate of premature death
Competing interests
Y. H.J. has received honoraria for lectures from AstraZeneca, Daiichi Sankyo/Lilly, Haemonetics, Nanosphere, Otsuka, and Sanofi Aventis; and research grants or support from Accumetrics, Boehringer Ingelheim, Han mi Pharmaceuticals, Haemonetics, and Otsuka. S.G. has received honoraria from Asteras, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Medtronic Japan, Mochida, MSD, Novartis, Otsuka, Pfizer, Sanofi Aventis, Takeda, and Tanabe Mitsubishi. He is an advisory board member for AstraZeneca, Bayer, MSD, and Pfizer/BMS. He is an investigator on a study or trial sponsored by AstraZeneca, Bayer, MSD, and Pfizer/BMS. J.L.A. served on an Acute Coronary Syndrome (ACS) Expert Panel to generate a position paper on advances in ACS therapy that was funded by an unrestricted educational grant from Sanofi Aventis (France). J.L.M. served as an investigator on a study or trial sponsored by Accumetrics, AstraZeneca, Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Nanosphere, and Sanofi Aventis. G.N.L., Y.H., K.T., and S.C.S. declare no competing interests.
from cardiovascular disease as well as global mortality associated with noncommunicable diseases.
Compelling evidence supports the use of dual anti-platelet therapy (DAPT) in patients with ACS and also those with stable ischaemic heart disease undergoing PCI. In these clinical settings, the use of a P2Y12 inhibi-tor combined with aspirin is recommended in the ACC/AHA and ESC guidelines.3–7 These recommendations are based primarily on large, phase III, randomized, con-trolled trials of these agents. In addition, patients who are poor responders or who have a high on-treatment plate-let reactivity to ADP during DAPT are at increased risk of ischaemic events after PCI.8 Multiple lines of evidence have suggested that low on-treatment platelet reactivity to ADP is associated with an increased risk of bleeding.8 Therefore, a ‘therapeutic window’ concept of platelet reactivity has been proposed for P2Y12-inhibitor therapy. However, the relationship between platelet reactivity and ischaemic or bleeding events might differ according to intrinsic thrombogenicity or disease activity.9
As with most cardiovascular drugs, P2Y12 inhibitors have shown marked interethnic differences in pharmaco-kinetic and pharmacodynamic profiles.9 Although East Asian ethnic groups are among the most populous (more than 1.5 billion people), very few East Asian patients have been included in the trials to assess the use of P2Y12 inhibitors, particularly the newer agents prasugrel and
急性冠脉综合征非血运重建患者抗血小板治疗中国专家共识_医学_高等教育_教育专区...ACS患者接受了单纯药物治疗 3级医院 PCI或 单纯药物 CABG 治疗 52% 37% PCI...
ACS非血运重建患者的抗血小板治疗中国专家共识 2009...ACS患者 19% 1% 80% 764 PCI 68 CABG 899 ...非血运重建治疗患者接受指南推荐药物治疗的情况如何?...
2014抗血小板药物治疗反应多样性临床检测和处理的中国专家建议_临床医学_医药卫生...国内随着 PCI 例数的大幅增长,优化抗血小板治疗、改善患者预后的重要性日益凸显...
卒中抗血小板治疗中国专家共识(2014年)_临床医学_...[24]中所有确诊 TIA 或可能 TIA 患者均接受卒中...关键在于在卒中和 TIA 患者中挑选出适宜双抗治疗的...
2014短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识(2014年)_临床医学_医药卫生_专业资料。 今日推荐 180份文档 CET四六级高分通关宝典...
? (3)无出血高危险的ACS 接受PCI 患者氯吡格雷 600 mg 负荷量后,150 mg/d,维持6d,之后 75 mg/d 维持。 抗血小板治疗用多久? PCI术后持续治疗12个月降低...
卒中抗血小板治疗中国专家共识(2014 年)_临床医学_...[24] 中所有确诊 TIA 或可能 TIA 患者均接受卒中...性病因需要抗凝治疗的患者,溶栓、同时排除具有出血...
遵循指南和共识 规范ACS患者的抗血小板治疗 1 遵循指南和共识 规范ACS患者的抗...血小板治疗中国专家共识》 19 中国的现状: 多数ACS患者未接受PCI治疗仅约1%的...
抗血小板治疗中国专家共识-寇惠娟Xin_临床医学_医药...指南推荐用于ACS或PCI 患者的三类抗血小板药物口服 1...用于之前未接受氯吡格雷治疗的患者,部分600 mg LD...
治疗中国专家共识 复习血小板GPⅡb/Ⅲa受体拮抗剂的使用时机 关于ACS & PCI ?...血流慢或者无复流或血栓性并发症,或没 有接受足量有效双联抗血小板治疗的患者...
热门文档